Online inquiry

IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14015MR)

This product GTTS-WQ14015MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL33 gene. The antibody can be applied in Chronic Obstructive Pulmonary Disease (COPD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens; Humanized
RefSeq NM_001199640.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 90865
UniProt ID O95760
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ14015MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ11489MR IVTScrip™ mRNA-Anti-MET, MetMAb(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MetMAb
GTTS-WQ12375MR IVTScrip™ mRNA-Anti-SAA1, NEOD-001(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA NEOD-001
GTTS-WQ15871MR IVTScrip™ mRNA-Anti-CD19, XmAb5871(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA XmAb5871
GTTS-WQ8372MR IVTScrip™ mRNA-Anti-TACSTD2, aTROP2S7(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA aTROP2S7
GTTS-WQ13812MR IVTScrip™ mRNA-Anti-S, REGN-10987(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA REGN-10987
GTTS-WQ13637MR IVTScrip™ mRNA-Anti-TNFSF4, R4930(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA R4930
GTTS-WQ5603MR IVTScrip™ mRNA-Anti-KDR, CDP791(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CDP791
GTTS-WQ9816MR IVTScrip™ mRNA-Anti-BTLA, JS004(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA JS004
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW